MedPath

The Effect of Low LEVel TrAgus STimulation on the Electrophysiological Substrate of Patients With Ischemic CardioMyopathy Substrate of Subjects With Ischemic CardioMyopathy

Not Applicable
Completed
Conditions
Ischemic Cardiomyopathy
Interventions
Device: Low level tragus stimulation
Registration Number
NCT03549468
Lead Sponsor
University of Oklahoma
Brief Summary

Patients with ischemic cardiomyopathy (left ventricular ejection fraction \<35%) and heart failure who already have an implantable device with an atrial lead (dual chamber defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham low level tragus stimulation (LLTS) (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3. Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min). The latter is required to examine the effect of LLTS on RA independent of heart rate. Repolarization alternans will be measured by analyzing a regular 12-lead ECG using a custom-made software.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
26
Inclusion Criteria
  1. Ischemic cardiomyopathy (LVEF <35%) and heart failure
  2. Implantable device with an atrial lead (dual chamber ICD or CRT-D)
  3. Sinus rhythm at the time of the study
Exclusion Criteria
  1. Recent (<6 months) stroke or myocardial infarction
  2. Persistent atrial fibrillation
  3. Recurrent vaso-vagal syncopal episodes
  4. Unilateral or bilateral vagotomy
  5. Pregnancy or breast feeding
  6. Uncontrolled diabetes or hypertension
  7. Sick sinus syndrome and 2nd or 3rd degree AV block (without a pacemaker)
  8. Bifascicular block or prolonged first degree block
  9. Hypotension due to autonomic dysfunction
  10. Inability or unwillingness to understand and/or sign informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
low level tragus stimulation (LLTS)Low level tragus stimulationPatients with ischemic cardiomyopathy (left ventricular ejection fraction \<35%) and heart failure who already have an implantable device with an atrial lead (dual chamber defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham LLTS (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3. Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min).
Primary Outcome Measures
NameTimeMethod
Repolarization alternans, an ECG measure for susceptibility to VT/VFduring acute stimulation procedure

Repolarization alternans will be measured by analyzing a regular 12-lead ECG using a custom-made software

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Oklahoma Health Sciences Center

🇺🇸

Oklahoma City, Oklahoma, United States

© Copyright 2025. All Rights Reserved by MedPath